Conclusions
glioma, difficult-to-treat malignant brain-tumour
MALIGNANCIES, GLIOMA, SOLID TUMOUR
2-OHOA demonstrated a good safety profile and encouraging activity in this difficult-to-treat malignant brain-tumour patient population, placing it as an ideal potential candidate for the treatment of glioma and other solid tumour malignancies.